|
1
|
Troiano NH: Physiologic and hemodynamic
changes during pregnancy. AACN Adv Crit Care. 29:273–283. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sierra-Laguado J, Garcia RG and
López-Jaramillo P: Flow-mediated dilatation of the brachial artery
in pregnancy. Int J Gynaecol Obstet. 93:60–61. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cid M and González M: Potential benefits
of physical activity during pregnancy for the reduction of
gestational diabetes prevalence and oxidative stress. Early Hum
Dev. 94:57–62. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sibai BM and Frangieh A: Maternal
adaptation to pregnancy. Curr Opin Obstet Gynecol. 7:420–426. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ahmed A and Perkins J: Angiogenesis and
intrauterine growth restriction. Baillieres Best Pract Res Clin
Obstet Gynaecol. 14:981–998. 2000. View Article : Google Scholar
|
|
6
|
Vrachnis N, Kalampokas E, Sifakis S,
Vitoratos N, Kalampokas T, Botsis D and Iliodromiti Z: Placental
growth factor (PlGF): A key to optimizing fetal growth. J Matern
Fetal Neonatal Med. 26:995–1002. 2013. View Article : Google Scholar
|
|
7
|
Sibai B, Dekker G and Kupferminc M:
Pre-eclampsia. Lancet. 365:785–799. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
No authors listed. Gestational
hypertension and preeclampsia: ACOG practice bulletin, number 222.
Obstet Gynecol. 135:e237–e260. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brown MA, Magee LA, Kenny LC, Karumanchi
SA, McCarthy FP, Saito S, Hall DR, Warren CE, Adoyi G and Ishaku S;
International Society for the Study of Hypertension in Pregnancy
(ISSHP): The hypertensive disorders of pregnancy: ISSHP
classification, diagnosis and management recommendations for
international practice. Hypertension. 72:24–43. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xiong X, Demianczuk NN, Saunders LD, Wang
FL and Fraser WD: Impact of preeclampsia and gestational
hypertension on birth weight by gestational age. Am J Epidemiol.
155:203–209. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Staff AC: The two-stage placental model of
preeclampsia: An update. J Reprod Immunol. 134-135:1–10. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Redman CW: Current topic: pre-eclampsia
and the placenta. Placenta. 12:301–308. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pankiewicz K, Szczerba E, Fijalkowska A,
Szamotulska K, Szewczyk G, Issat T and Maciejewski TM: The
association between serum galectin-3 level and its placental
production in patients with preeclampsia. J Physiol Pharmacol.
71:845–856. 2020.
|
|
14
|
Redman CWG and Staff AC: Preeclampsia,
biomarkers, syncytiotrophoblast stress, and placental capacity. Am
J Obstet Gynecol. 213(Suppl 4): S9.e1–S9.e4. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maynard SE, Venkatesha S, Thadhani R and
Karumanchi SA: Soluble Fms-like tyrosine kinase 1 and endothelial
dysfunction in the pathogenesis of preeclampsia. Pediatr Res.
57:1R–7R. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Koga K, Osuga Y, Yoshino O, Hirota Y,
Ruimeng X, Hirata T, Takeda S, Yano T, Tsutsumi O and Taketani Y:
Elevated serum soluble vascular endothelial growth factor receptor
1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol
Metab. 88:2348–2351. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tsatsaris V, Goffin F and Foidart JM:
Circulating angiogenic factors and preeclampsia. N Engl J Med.
350:2003–2004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Levine RJ, Maynard SE, Qian C, Lim KH,
England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein
FH, et al: Circulating angiogenic factors and the risk of
preeclampsia. N Engl J Med. 350:672–683. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Maynard SE and Karumanchi SA: Angiogenic
factors and preeclampsia. Semin Nephrol. 31:33–46. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pratt A, Da Silva Costa F, Borg AJ,
Kalionis B, Keogh R and Murthi P: Placenta-derived angiogenic
proteins and their contribution to the pathogenesis of
preeclampsia. Angiogenesis. 18:115–123. 2015. View Article : Google Scholar
|
|
21
|
Helmo FR, Lopes AMM, Carneiro ACDM, Campos
CG, Silva PB, Dos Reis Monteiro MLG, Rocha LP, Dos Reis MA,
Etchebehere RM, Machado JR and Corrêa RRM: Angiogenic and
antiangiogenic factors in preeclampsia. Pathol Res Pract. 214:7–14.
2018. View Article : Google Scholar
|
|
22
|
Ferrara N and Kerbel RS: Angiogenesis as a
therapeutic target. Nature. 438:967–974. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kendall RL and Kenneth AT: Inhibition of
vascular endothelial cell growth factor activity by an endogenously
encoded soluble receptor. Proc Natl Acad Sci USA. 90:10705–10709.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Clark DE, Smith SK, He Y, Day KA, Licence
DR, Corps AN, Lammoglia R and Charnock-Jones DS: A vascular
endothelial growth factor antagonist is produced by the human
placenta and released into the maternal circulation. Biol Reprod.
59:1540–1548. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Taylor RN, Grimwood J, Taylor RS, McMaster
MT, Fisher SJ and North RA: Longitudinal serum concentrations of
placental growth factor: Evidence for abnormal placental
angiogenesis in pathologic pregnancies. Am J Obstet Gynecol.
188:177–182. 2003. View Article : Google Scholar
|
|
26
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hirashima C, Ohkuchi A, Arai F, Takahashi
K, Suzuki H, Watanabe T, Kario K, Matsubara S and Suzuki M:
Establishing reference values for both total soluble Fms-like
tyrosine kinase 1 and free placental growth factor in pregnant
women. Hypertens Res. 28:727–732. 2005. View Article : Google Scholar
|
|
28
|
Azimi-Nezhad M: Vascular endothelial
growth factor from embryonic status to cardiovascular pathology.
Rep Biochem Mol Biol. 2:59–69. 2014.PubMed/NCBI
|
|
29
|
Vincenti V, Cassano C, Rocchi M and
Persico G: Assignment of the vascular endothelial growth factor
gene to human chromosome 6p21.3. Circulation. 93:1493–1495. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Maglione D, Guerriero V, Viglietto G,
Delli-Bovi P and Persico MG: Isolation of a human placenta cDNA
coding for a protein related to the vascular permeability factor.
Proc Natl Acad Sci USA. 88:9267–9271. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
De Falco S: The discovery of placenta
growth factor and its biological activity. Exp Mol Med. 44:1–9.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Park JE, Chen HH, Winer J, Houck KA and
Ferrara N: Placenta growth factor. Potentiation of vascular
endothelial growth factor bioactivity, in vitro and in vivo, and
high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem.
269:25646–25654. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lee ES, Oh MJ, Jung JW, Lim JE, Seol HJ,
Lee KJ and Kim HJ: The levels of circulating vascular endothelial
growth factor and soluble Flt-1 in pregnancies complicated by
preeclampsia. J Korean Med Sci. 22:94–98. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Roberts JM and Rajakumar A: Preeclampsia
and soluble fms-like tyrosine kinase 1. J Clin Endocrinol Metab.
94:2252–2254. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Palmer KR, Kaitu'u-Lino TJ, Hastie R,
Hannan NJ, Ye L, Binder N, Cannon P, Tuohey L, Johns TG, Shub A and
Tong S: Placental-specific sFLT-1 e15a protein is increased in
preeclampsia, antagonizes vascular endothelial growth factor
signaling, and has antiangiogenic activity. Hypertension.
66:1251–1259. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hastie R, Brownfoot FC, Pritchard N,
Hannan NJ, Cannon P, Nguyen V, Palmer K, Beard S, Tong S and
Kaitu'u-Lino TJ: EGFR (epidermal growth factor receptor) signaling
and the mitochondria regulate sFlt-1 (soluble FMS-Like tyrosine
kinase-1) secretion. Hypertension. 73:659–670. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Levine RJ, Lam C, Qian C, Yu KF, Maynard
SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, et al:
Soluble endoglin and other circulating antiangiogenic factors in
preeclampsia. N Engl J Med. 355:992–1005. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Maynard SE, Min JY, Merchan J, Lim KH, Li
J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, et
al: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may
contribute to endothelial dysfunction, hypertension, and
proteinuria in preeclampsia. J Clin Invest. 111:649–658. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Thadhani R, Mutter WP, Wolf M, Levine RJ,
Taylor RN, Sukhatme VP, Ecker J and Karumanchi SA: First trimester
placental growth factor and soluble fms-like tyrosine kinase 1 and
risk for preeclampsia. J Clin Endocrinol Metab. 89:770–775. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chaiworapongsa T, Romero R, Kim YM, Kim
GJ, Kim MR, Espinoza J, Bujold E, Gonçalves L, Gomez R, Edwin S and
Mazor M: Plasma soluble vascular endothelial growth factor
receptor-1 concentration is elevated prior to the clinical
diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med. 17:3–18.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Buhimschi CS, Norwitz ER, Funai E, Richman
S, Guller S, Lockwood CJ and Buhimschi IA: Urinary angiogenic
factors cluster hypertensive disorders and identify women with
severe preeclampsia. Am J Obstet Gynecol. 192:734–741. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ohkuchi A, Hirashima C, Matsubara S,
Suzuki H, Takahashi K, Arai F, Watanabe T, Kario K and Suzuki M:
Alterations in placental growth factor levels before and after the
onset of preeclampsia are more pronounced in women with early onset
severe preeclampsia. Hypertens Res. 30:151–159. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Stepan H, Unversucht A, Wessel N and Faber
R: Predictive value of maternal angiogenic factors in second
trimester pregnancies with abnormal uterine perfusion.
Hypertension. 49:818–824. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
De Vivo A, Baviera G, Giordano D,
Todarello G, Corrado F and D'anna R: Endoglin, PlGF and sFlt-1 as
markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand.
87:837–842. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Romero R, Nien JK, Espinoza J, Todem D, Fu
W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-Tovi S, et al: A
longitudinal study of angiogenic (placental growth factor) and
anti-angiogenic (soluble endoglin and soluble vascular endothelial
growth factor receptor-1) factors in normal pregnancy and patients
destined to develop preeclampsia and deliver a small for
gestational age neonate. J Matern Fetal Neonatal Med. 21:9–23.
2008. View Article : Google Scholar :
|
|
46
|
Ohkuchi A, Hirashima C, Suzuki H,
Takahashi K, Yoshida M, Matsubara S and Suzuki M: Evaluation of a
new and automated electrochemiluminescence immunoassay for plasma
sFlt-1 and PlGF levels in women with preeclampsia. Hypertens Res.
33:422–427. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Verlohren S, Galindo A, Schlembach D,
Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B and
Stepan H: An automated method for the determination of the
sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet
Gynecol. 202:161.e1–161.e11. 2010. View Article : Google Scholar
|
|
48
|
Sunderji S, Gaziano E, Wothe D, Rogers LC,
Sibai B, Karumanchi SA and Hodges-Savola C: Automated assays for
sVEGF R1 and PlGF as an aid in the diagnosis of preterm
preeclampsia: A prospective clinical study. Am J Obstet Gynecol.
202:40.e1–e77. 2010. View Article : Google Scholar
|
|
49
|
Chaiworapongsa T, Romero R, Savasan ZA,
Kusanovic JP, Ogge G, Soto E, Dong Z, Tarca A, Gaurav B and Hassan
SS: Maternal plasma concentrations of angiogenic/anti-angiogenic
factors are of prognostic value in patients presenting to the
obstetrical triage area with the suspicion of preeclampsia. J
Matern Fetal Neonatal Med. 24:1187–1207. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Rana S, Powe CE, Salahuddin S, Verlohren
S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R and
Karumanchi SA: Angiogenic factors and the risk of adverse outcomes
in women with suspected preeclampsia. Circulation. 125:911–919.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Moore AG, Young H, Keller JM, Ojo LR, Yan
J, Simas TA and Maynard SE: Angiogenic biomarkers for prediction of
maternal and neonatal complications in suspected preeclampsia. J
Matern Fetal Neonatal Med. 25:2651–2657. 2012. View Article : Google Scholar
|
|
52
|
Verlohren S, Herraiz I, Lapaire O,
Schlembach D, Moertl M, Zeisler H, Calda P, Holzgreve W, Galindo A,
Engels T, et al: The sFlt-1/PlGF ratio in different types of
hypertensive pregnancy disorders and its prognostic potential in
preeclamptic patients. Am J Obstet Gynecol. 206:58.e1–e8. 2012.
View Article : Google Scholar
|
|
53
|
Herraiz I, Dröge LA, Gómez-Montes E,
Henrich W, Galindo A and Verlohren S: Characterization of the
soluble fms-like tyrosine kinase-1 to placental growth factor ratio
in pregnancies complicated by fetal growth restriction. Obstet
Gynecol. 124:265–273. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Chaiworapongsa T, Romero R, Korzeniewski
SJ, Cortez JM, Pappas A, Tarca AL, Chaemsaithong P, Dong Z, Yeo L
and Hassan SS: Plasma concentrations of angiogenic/anti-angiogenic
factors have prognostic value in women presenting with suspected
preeclampsia to the obstetrical triage area: a prospective study. J
Matern Fetal Neonatal Med. 27:132–144. 2014. View Article : Google Scholar :
|
|
55
|
Rana S, Schnettler WT, Powe C, Wenger J,
Salahuddin S, Cerdeira AS, Verlohren S, Perschel FH, Arany Z, Lim
KH, et al: Clinical characterization and outcomes of preeclampsia
with normal angiogenic profile. Hypertens Pregnancy. 32:189–201.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Gómez-Arriaga PI, Herraiz I, López-Jiménez
EA, Escribano D, Denk B and Galindo A: Uterine artery Doppler and
sFlt-1/PlGF ratio: Prognostic value in early-onset pre-eclampsia.
Ultrasound Obstet Gynecol. 43:525–532. 2014. View Article : Google Scholar
|
|
57
|
Garcia-Tizon Larroca S, Tayyar A, Poon LC,
Wright D and Nicolaides KH: Competing risks model in screening for
preeclampsia by biophysical and biochemical markers at 30-33 weeks'
gestation. Fetal Diagn Ther. 36:9–17. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Verlohren S, Herraiz I, Lapaire O,
Schlembach D, Zeisler H, Calda P, Sabria J, Markfeld-Erol F,
Galindo A, Schoofs K, et al: New gestational phase-specific cutoff
values for the use of the soluble fms-like tyrosine
kinase-1/placental growth factor ratio as a diagnostic test for
preeclampsia. Hypertension. 63:346–352. 2014. View Article : Google Scholar
|
|
59
|
Schoofs K, Grittner U, Engels T, Pape J,
Denk B, Henrich W and Verlohren S: The importance of repeated
measurements of the sFlt-1/PlGF ratio for the prediction of
preeclampsia and intrauterine growth restriction. J Perinat Med.
42:61–68. 2014. View Article : Google Scholar
|
|
60
|
Zhang J, Klebanoff MA and Roberts JM:
Prediction of adverse outcomes by common definitions of
hypertension in pregnancy. Obstet Gynecol. 97:261–267.
2001.PubMed/NCBI
|
|
61
|
No authors listed. ACOG practice bulletin
no. 202: Gestational hypertension and preeclampsia. Obstet Gynecol.
133:12019.
|
|
62
|
Bujold E, Roberge S, Lacasse Y, Bureau M,
Audibert F, Marcoux S, Forest JC and Giguère Y: Prevention of
preeclampsia and intrauterine growth restriction with aspirin
started in early pregnancy: A meta-analysis. Obstet Gynecol.
116:402–414. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
National Institute for Health and Care
Excellence (NICE): PlGF-based testing to help diagnose suspected
preterm pre-eclampsia. https://www.nice.org.uk/guidance/dg49. Accessed July
27, 2022
|
|
64
|
Dröge LA, Perschel FH, Stütz N, Gafron A,
Frank L, Busjahn A, Henrich W and Verlohren S: Prediction of
preeclampsia-related adverse outcomes with the sFlt-1 (soluble
fms-like tyrosine kinase 1)/PlGF (placental growth factor)-ratio in
the clinical routine: A real-world study. Hypertension. 77:461–471.
2021. View Article : Google Scholar
|
|
65
|
Hughes RCE, Phillips I, Florkowski CM and
Gullam J: The predictive value of the sFlt-1/PlGF ratio in
suspected preeclampsia in a New Zealand population: A prospective
cohort study. Aust N Z J Obstet Gynaecol. 63:34–41. 2023.
View Article : Google Scholar
|
|
66
|
Hund M, Allegranza D, Schoedl M, Dilba P,
Verhagen-Kamerbeek W and Stepan H: Multicenter prospective clinical
study to evaluate the prediction of short-term outcome in pregnant
women with suspected preeclampsia (PROGNOSIS): Study protocol. BMC
Pregnancy Childbirth. 14:3242014. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zeisler H, Llurba E, Chantrain F, Vatish
M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H,
Allegranza D, et al: Predictive value of the sFlt-1:PlGF ratio in
women with suspected preeclampsia. New Engl J Med. 374:13–22. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Hund M, Verhagen-Kamerbeek W, Reim M,
Messinger D, van der Does R and Stepan H: Influence of the
sFlt-1/PlGF ratio on clinical decision-making in women with
suspected preeclampsia-the PreOS study protocol. Hypertens
Pregnancy. 34:102–115. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Klein E, Schlembach D, Ramoni A, Langer E,
Bahlmann F, Grill S, Schaffenrath H, van der Does R, Messinger D,
Verhagen-Kamerbeek WD, et al: Influence of the sFlt-1/PlGF ratio on
clinical decision-making in women with suspected preeclampsia. PLoS
One. 11:e01560132016. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Perales A, Delgado JL, de la Calle M,
García-Hernández JA, Escudero AI, Campillos JM, Sarabia MD, Laíz B,
Duque M, Navarro M, et al: sFlt-1/PlGF for prediction of
early-onset pre-eclampsia: STEPS (study of early pre-eclampsia in
Spain). Ultrasound Obstet Gynecol. 50:373–382. 2017. View Article : Google Scholar
|
|
71
|
Herraiz I, Simón E, Gómez-Arriaga PI,
Quezada MS, García-Burguillo A, López-Jiménez EA and Galindo A:
Clinical implementation of the sFlt-1/PlGF ratio to identify
preeclampsia and fetal growth restriction: A prospective cohort
study. Pregnancy Hypertens. 13:279–285. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Sabriá E, Lequerica-Fernández P,
Lafuente-Ganuza P, Eguia-Ángeles E, Escudero AI, Martínez-Morillo
E, Barceló C and Álvarez FV: Addition of N-terminal pro-B
natriuretic peptide to soluble fms-like tyrosine kinase-1/placental
growth factor ratio >38 improves prediction of pre-eclampsia
requiring delivery within 1 week: A longitudinal cohort study.
Ultrasound Obstet Gynecol. 51:758–767. 2018. View Article : Google Scholar
|
|
73
|
Lafuente-Ganuza P, Lequerica-Fernandez P,
Carretero F, Escudero AI, Martinez-Morillo E, Sabria E, Herraiz I,
Galindo A, Lopez A, Martinez-Triguero ML and Alvarez FV: A more
accurate prediction to rule in and rule out pre-eclampsia using the
sFlt-1/PlGF ratio and NT-proBNP as biomarkers. Clin Chem Lab Med.
58:399–407. 2020. View Article : Google Scholar
|
|
74
|
Sovio U, White IR, Dacey A, Pasupathy D
and Smith GCS: Screening for fetal growth restriction with
universal third trimester ultrasonography in nulliparous women in
the pregnancy outcome prediction (POP) study: A prospective cohort
study. Lancet. 386:2089–2097. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Zeisler H, Llurba E, Chantraine FJ, Vatish
M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H,
Allegranza D, et al: Soluble fms-like tyrosine kinase-1 to
placental growth factor ratio: Ruling out pre-eclampsia for up to 4
weeks and value of retesting. Ultrasound Obstet Gynecol.
53:367–375. 2019. View Article : Google Scholar :
|
|
76
|
Bian X, Biswas A, Huang X, Lee KJ, Li TK,
Masuyama H, Ohkuchi A, Park JS, Saito S, Tan KH, et al: Short-term
prediction of adverse outcomes using the sFlt-1 (soluble fms-like
tyrosine kinase 1)/PlGF (placental growth factor) ratio in Asian
women with suspected preeclampsia. Hypertension. 74:164–172. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Cerdeira AS, O'Sullivan J, Ohuma EO,
Harrington D, Szafranski P, Black R, Mackillop L, Impey L,
Greenwood C, James T, et al: Randomized interventional study on
prediction of preeclampsia/eclampsia in women with suspected
preeclampsia: INSPIRE. Hypertension. 74:983–990. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Cerdeira AS, O'Sullivan J, Ohuma EO, James
T, Papageorghiou AT, Knight M and Vatish M: Ruling out preeclampsia
in the next 4 weeks using a soluble fms-like tyrosine kinase
1/placental growth factor ratio ≤38: Secondary analysis of the
interventional study on prediction of preeclampsia/eclampsia in
women with suspected preeclampsia. Am J Obstet Gynecol.
226:443–445. 2022. View Article : Google Scholar
|
|
79
|
Perry H, Binder J, Kalafat E, Jones S,
Thilaganathan B and Khalil A: Angiogenic marker prognostic models
in pregnant women with hypertension. Hypertension. 75:755–761.
2020. View Article : Google Scholar
|
|
80
|
Peguero A, Fernandez-Blanco L, Mazarico E,
Benitez L, Gonzalez A, Youssef L, Crispi F, Hernandez S and
Figueras F: Added prognostic value of longitudinal changes of
angiogenic factors in early-onset severe pre-eclampsia: A
prospective cohort study. BJOG. 128:158–165. 2021. View Article : Google Scholar
|
|
81
|
Dathan-Stumpf A, Czarnowsky V, Hein V,
Andraczek T and Stepan H: Real-world data on the clinical use of
angiogenic factors in pregnancies with placental dysfunction. Am J
Obstet Gynecol. 226(2S): S1037–S1047.e2. 2022. View Article : Google Scholar
|
|
82
|
Kifle MM, Dahal P, Vatish M, Cerdeira AS
and Ohuma EO: The prognostic utility of soluble fms-like tyrosine
kinase-1 (sFlt-1) and placental growth factor (PIGF) biomarkers for
predicting preeclampsia: A secondary analysis of data from the
INSPIRE trial. BMC Pregnancy Childbirth. 22:5202022. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Chaemsaithong P, Sahota DS and Poon LC:
First trimester preeclampsia screening and prediction. Am J Obstet
Gynecol. 226(2S): S1071–S1097.e2. 2022. View Article : Google Scholar
|
|
84
|
Crovetto F, Figueras F, Triunfo S, Crispi
F, Rodriguez-Sureda V, Peguero A, Dominguez C and Gratacos E: Added
value of angiogenic factors for the prediction of early and late
preeclampsia in the first trimester of pregnancy. Fetal Diagn Ther.
35:258–266. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Crovetto F, Figueras F, Triunfo S, Crispi
F, Rodriguez-Sureda V, Dominguez C, Llurba E and Gratacós E: First
trimester screening for early and late preeclampsia based on
maternal characteristics, biophysical parameters, and angiogenic
factors. Prenat Diagn. 35:183–191. 2015. View Article : Google Scholar
|
|
86
|
Lamain-de Ruiter M, Kwee A, Naaktgeboren
CA, Louhanepessy RD, De Groot I, Evers IM, Groenendaal F, Hering
YR, Huisjes AJM, Kirpestein C, et al: External validation of
prognostic models for preeclampsia in a Dutch multicenter
prospective cohort. Hypertens Pregnancy. 38:78–88. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Tsiakkas A, Mendez O, Wright A, Wright D
and Nicolaides KH: Maternal serum soluble fms-like tyrosine
kinase-1 at 12, 22, 32 and 36 weeks' gestation in screening for
pre-eclampsia. Ultrasound Obstet Gynecol. 47:478–483. 2016.
View Article : Google Scholar
|
|
88
|
Diguisto C, Piver E, Gouge AL, Eboue F,
Vaillant CL, Maréchaud M, Goua V, Giraudeau B and Perrotin F: First
trimester uterine artery Doppler, sFlt-1 and PlGF to predict
preeclampsia in a high-risk population. J Matern Fetal Neonatal
Med. 30:1514–1519. 2017. View Article : Google Scholar
|
|
89
|
Verlohren S, Brennecke SP, Galindo A,
Karumanchi SA, Mirkovic LB, Schlembach D, Stepan H, Vatish M,
Zeisler H and Rana S: Clinical interpretation and implementation of
the sFlt-1/PlGF ratio in the prediction, diagnosis and management
of preeclampsia. Pregnancy Hypertens. 27:42–50. 2022. View Article : Google Scholar
|
|
90
|
Dathan-Stumpf A, Rieger A, Verlohren S,
Wolf C and Stepan H: sFlt-1/PlGF ratio for prediction of
preeclampsia in clinical routine: A pragmatic real-world analysis
of healthcare resource utilisation. PLoS One. 17:e02634432022.
View Article : Google Scholar : PubMed/NCBI
|
